One of the biggest challenges facing any Pharma rep is the increasing number of doctors who won’t see them. Every week, more and more physicians are restricting, and some even eliminating, their face time with sales reps.
In fact, the number of doctors willing to see reps has declined by about 20% since 2008. And while some clinicians chose to do this, others have had it thrust upon them by their institutions or employers who are concerned that medical practice may be unduly influenced by pharmaceutical industry representatives.
Although “no see” advocates argue that removing commercial influence is better for patients, a new study suggests the practice has downsides too.
This should be good news for the Pharma, who has always maintained that the clampdown on reps amounts to overkill and that more than selling, reps provide information that can benefit patients.
The study, published in the Journal of Clinical Hypertension, divided medical practices into four categories. Based on the degree of sales representative access to clinicians, they were classified as either very low, low, medium, or high.
The clinical decisions, and prescribing behavior of over 72,000 physicians were then statistically analyzed, with regards to the drugs listed below:
- Januvia® (sitagliptin tablets) – an innovative drug for type 2 diabetes
- Avandia® (rosiglitazone) – an older diabetes drug with a new FDA–required black box warning for cardiovascular safety
- Vytorin® (simvastatin + ezetimbe) – a combination lipid-lowering therapy that had negative outcomes in a clinical trial
The authors found that after the FDA approved Januvia, docs who had little interaction with reps took longer to write prescriptions than docs whose access to reps was not as restricted. Meanwhile, physicians who rarely, if ever, saw reps were slowest to change their prescribing habits after negative news emerged about Avandia and Vytorin .
Specifically, the study found that docs with very low access to reps had the lowest adoption rates for Januvia. They took between 1.6 and 4.6 times longer to start writing prescriptions after the pill was launched than docs who had low, medium or high access to reps. Docs who had very low access to reps were also 4 times slower than those of their counterparts to reduce their use of Avandia, after the Black Box warning was issued in 2007. There was also “significantly less” change in the prescribing habits of those who had less access to reps in response to controversial and disappointing trial results released in 2008 for Vytorin, than those with fewer restrictions on rep interactions.
The study authors commented, “These findings emphasize that limiting access to pharmaceutical representatives can have the unintended effect of reducing appropriate responses to negative information about drugs just as much as responses to positive information about innovative drugs.”
“The study affirms simple intuition that when physicians have to make decisions involving complex issues with less than complete information available to them, and where the consequence of a wrong decision is significant… unintended consequences are likely to appear. Policies that promote physician ignorance of new medical information resulting from access limits, run counter to protecting patient health.”
Could increasing, rather than decreasing sales representative access to physicians lead to better clinical decision making and better patient health? Let us know what you think.